Piyasa kapalı· · ILA · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
NMPA approval supported by a 200-subject, randomized, controlled study in China demonstrating statistically significant improvement in mid-to-lower facial wrinkles and a favorable safety profile China represents a growing medical aesthetic market, with the market for non-invasive/minimally invasive procedures valued at RMB 146.0 billion (approximately US$20.6 billion) in 20231 SAN CLEMENTE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthe
SAN CLEMENTE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference on September 8-10, 2026. About Sofwave MedicalSofwave Medical Ltd. (TASE: SOFW) is a global
A prospective randomized controlled trial of an aesthetic EMS platform to assess objective functional performance reports improvements across four standardized testsSAN CLEMENTE, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthetics company advancing non-invasive technologies for skin and body, today announced the publication of data from a new randomized controlled clinical study of the Company’s proprietary PlyoPulse™ technology, titled “
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.